Evidence map›Paper›PMID 39976192›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Applying Ultrasound to Mechanically and Noninvasively Sensitize Prostate Tumors to TRAIL-Mediated Apoptosis.

Abigail R Fabiano, Malachy W Newman, Jenna A Dombroski, Schyler J Rowland, Samantha V Knoblauch, Jiro Kusunose, Katherine N Gibson-Corley, Benjamin G Kaufman, Liqin Ren, Charles F Caskey and 1 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. PIEZO2 in tumors: from mechanobiological switches to activity-targeted therapies.Journal of experimental & clinical cancer research : CR · 2025
    Review
  7. Wearable bioelectronics for cancer theranostics.Microsystems & nanoengineering · 2025
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Abigail R FabianoDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Malachy W NewmanDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Jenna A DombroskiDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Schyler J RowlandDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Samantha V KnoblauchDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Jiro KusunoseVanderbilt University Institute of Imaging Science, Vanderbilt University Medical Center, Nashville, TN, 37235, USA.
Katherine N Gibson-CorleyDepartment of Pathology, Microbiology and Immunology, Division of Comparative Medicine, Vanderbilt University Medical Center, Nashville, TN, 37235, USA.
Benjamin G KaufmanDepartment of Bioengineering, Rice University, Houston, TX, 77005, USA.
Liqin RenDepartment of Bioengineering, Rice University, Houston, TX, 77005, USA.
Charles F CaskeyDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, 37235, USA.
Michael R KingDepartment of Bioengineering, Rice University, Houston, TX, 77005, USA.ORCID https://orcid.org/0000-0002-0223-7808

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Enabling Technology to Study Mechanosensitive and Mechanoresistant Cancer Cells in FlowR01CA256054 · NCI · VANDERBILT UNIVERSITY · PI KING, MICHAEL R. · 2021 to 2025
$1.8M
Leica Bond RXS10OD023475 · OD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BOYD, KELLI L. · 2018 to 2018
$213k
Cancer Prevention and Research Institute of Texas RR230029National Science Foundation Graduate Research Fellowship Program 2021314768NCI/NIH Cancer Center Support P30CA068485NCI NIH HHS P30 CA068485NCI NIH HHS R01 CA256054NCI NIH HHS R01CA256054NIH HHS S10 OD023475Shared Instrumentation S10 OD023475-01A1
6 · The paper itself

Abstract

Non-surgical and safe prostate cancer (PCa) therapies are in demand. Soluble tumor necrosis factor (TNF-α) related apoptosis inducing ligand (TRAIL), a cancer-specific drug, shows preclinical efficacy but has a short circulation half-life. This research has shown that physiological fluid shear stress activates mechanosensitive ion channels (MSCs), such as Piezo1, enhancing TRAIL-mediated apoptosis in cancer cells. Herein, noninvasive, focal ultrasound (FUS) is implemented to augment the pro-apoptotic effects of TRAIL. Using thermally safe FUS parameters, it is observed that TRAIL sensitivity increases with higher FUS pressure in PCa cells, mediated by Piezo1. This is confirmed by examining the effects of calcium chelation, MSC inhibitors, and PIEZO knockdown. In vivo, a multi-dose study with 10 min FUS exposure shows that 0 and 4-h intervals between TRAIL and FUS significantly reduce tumor burden, with an increase in apoptosis evident by enhanced cleaved-caspase 3 expression. This mechanotherapy offers a clinically translatable approach by utilizing widely available FUS technology, applicable to treat additional cancer types.

Indexed as

ApoptosisProstatic NeoplasmsTNF-Related Apoptosis-Inducing LigandUltrasonic TherapyAnimalsCell Line, TumorHumansIon ChannelsMaleMiceIon ChannelsTNF-Related Apoptosis-Inducing LigandTNFSF10 protein, humanmechanotherapymechanotransductionnoninvasivesynergistictherapeutic ultrasound

Identifiers

PMID39976192
PMCPMC12005757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.